Disclosure Insight Maintains Medium Risk Rating on Watson Pharmaceuticals

A report from Disclosure Insight reiterates its Medium Risk – Negative Bias rating on Watson Pharmaceuticals (NYSE: WPI).

The report states, “Non-SEC investigative activity; litigation; concentrated revenue; and acquisition activity support our opinion of a Medium Risk - Negative Bias rating on WPI. Ongoing investigative activity as of the 10-Q filed 1-Nov-11 included state attorney general inquiries and qui tam actions to determine whether alleged improper pricing efforts by pharmaceutical manufacturers led to overpayments by Medicare and Medicaid and an FTC Civil Investigative Demand seeking information related to the terms of lawsuit settlements with certain patentees.”

WPI closed yesterday at $65.83.